WO2006123226A3 - An inhibitor of mtor for inhibiting the formation of scar tissue - Google Patents

An inhibitor of mtor for inhibiting the formation of scar tissue

Info

Publication number
WO2006123226A3
WO2006123226A3 PCT/IB2006/001300 IB2006001300W WO2006123226A3 WO 2006123226 A3 WO2006123226 A3 WO 2006123226A3 IB 2006001300 W IB2006001300 W IB 2006001300W WO 2006123226 A3 WO2006123226 A3 WO 2006123226A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
surgery
disease
mtor
impregnated
prevent
Prior art date
Application number
PCT/IB2006/001300
Other languages
French (fr)
Other versions
WO2006123226A2 (en )
Inventor
Hugo Barrie Nel
Original Assignee
Villiers Malan De
Hugo Barrie Nel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine

Abstract

The invention describes the use of an inhibitor of the mammalian Target of Rapamycin (mTOR), such as sirolimus or everolimus, to effect a clinical response on an insult or wound. The compound can be administered in any suitable local or topical delivery form, such as by local injection; local delivery systems, for example impregnated implants and slow release devices; forms of dressings, impregnated suturing material; impregnated mesh, sheets, membranes, prosthetics; gels containing the compound; and so forth. Typical applications where it would be useful to prevent scarring by inhibiting the mTOR according to the invention are: cosmetic surgery; scar revision surgery, including excision of scars and contracture release; tendon repair; nerve repair; and fibrotic or inflammatory conditions, such as de Quervain's disease, Peyronie's disease, plantar fasciitis, Dupuytren's disease, finger triggering, forms of synovitis, such as rheumatoid arthritis, after laparotomy to prevent adhesions, after brain surgery to prevent gliosis, and microsurgery, such as microvascular surgery and fallopian tube surgery.
PCT/IB2006/001300 2005-05-18 2006-05-18 An inhibitor of mtor for inhibiting the formation of scar tissue WO2006123226A3 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US68258105 true 2005-05-18 2005-05-18
ZA2005/04008 2005-05-18
US60/682,581 2005-05-18
ZA200504008 2005-05-18

Publications (2)

Publication Number Publication Date
WO2006123226A2 true WO2006123226A2 (en) 2006-11-23
WO2006123226A3 true true WO2006123226A3 (en) 2007-01-11

Family

ID=36968953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001300 WO2006123226A3 (en) 2005-05-18 2006-05-18 An inhibitor of mtor for inhibiting the formation of scar tissue

Country Status (1)

Country Link
WO (1) WO2006123226A3 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009030931A1 (en) 2009-06-24 2010-12-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Surgical wound sealing element for sealing wound in surgical joint in e.g. intestine of human, has body coated with anti-inflammatory composition and designed as thread that comprises fibers, which are interlaced together
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
WO2015121836A1 (en) 2014-02-14 2015-08-20 Druggability Technologies Ip Holdco Limited Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2016130485A1 (en) * 2015-02-09 2016-08-18 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to prevent and regress adhesions and fibrosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087613A1 (en) * 2002-01-29 2004-05-06 Molmenti Ernesto P. Prevention of adhesions with rapamycin
WO2004110347A2 (en) * 2003-05-07 2004-12-23 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US20040087613A1 (en) * 2002-01-29 2004-05-06 Molmenti Ernesto P. Prevention of adhesions with rapamycin
WO2004110347A2 (en) * 2003-05-07 2004-12-23 Afmedica, Inc. Compositions and methods for reducing scar tissue formation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM A ET AL: "Are keloids really "gli-loids"?: High-level expression of gli-1 oncogene in keloids.", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. NOV 2001, vol. 45, no. 5, November 2001 (2001-11-01), pages 707 - 711, XP002399754, ISSN: 0190-9622 *

Also Published As

Publication number Publication date Type
WO2006123226A2 (en) 2006-11-23 application

Similar Documents

Publication Publication Date Title
Nienhuijs et al. Chronic pain after mesh repair of inguinal hernia: a systematic review
Venkatraman et al. Release profiles in drug-eluting stents: issues and uncertainties
Serruys et al. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?
Campoccia et al. The significance of infection related to orthopedic devices and issues of antibiotic resistance
Andersson et al. Laparoscopic extraperitoneal inguinal hernia repair versus open mesh repair: a prospective randomized controlled trial
Kasperk et al. The repair of large parastomal hernias using a midline approach and a prosthetic mesh in the sublay position
US20090018559A1 (en) Temporarily Stiffened Mesh Prostheses
Katkhouda et al. Use of fibrin sealant for prosthetic mesh fixation in laparoscopic extraperitoneal inguinal hernia repair
Schwab et al. Less chronic pain following mesh fixation using a fibrin sealant in TEP inguinal hernia repair
Sanchez et al. Mesh infection in ventral incisional hernia repair: incidence, contributing factors, and treatment
Uhlig et al. Suprathel®—An innovative, resorbable skin substitute for the treatment of burn victims
Catena et al. Use of porcine dermal collagen graft (Permacol) for hernia repair in contaminated fields
Chastan Tension-free open hernia repair using an innovative self-gripping semi-resorbable mesh
Agarwal et al. Prospective double-blind randomized controlled study comparing heavy-and lightweight polypropylene mesh in totally extraperitoneal repair of inguinal hernia: early results
US20040071756A1 (en) Devices and methods for reducing scar tissue formation
Noel et al. Chitosan films: a potential local drug delivery system for antibiotics
US20070299043A1 (en) Anti-scarring drug combinations and use thereof
Fortelny et al. Use of fibrin sealant (Tisseel/Tissucol) in hernia repair: a systematic review
Pring et al. Laparoscopic versus open ventral hernia repair: a randomized controlled trial
Rosen Polyester-based mesh for ventral hernia repair: is it safe?
Schwab et al. Biomechanical analyses of mesh fixation in TAPP and TEP hernia repair
Kukleta et al. Efficiency and safety of mesh fixation in laparoscopic inguinal hernia repair using n-butyl cyanoacrylate: long-term biocompatibility in over 1,300 mesh fixations
ABDEL‐FATTAH et al. How common are tape erosions? A comparison of two versions of the transobturator tension‐free vaginal tape procedure
Silva et al. Recent progress in flexor tendon healing
Puskas et al. Drug‐eluting stent coatings

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06744723

Country of ref document: EP

Kind code of ref document: A2